The downregulation of FABP4 upon LCM treatment suggests a potential dual benefit of LCM in both reducing lipid accumulation and modulating inflammatory responses, which are often interconnected in metabolic disorders. This evidence concerns the gene FABP4 and Other metabolic disease.